Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study

Ashish V. Chintakuntlawar; Kandelaria M. Rumilla; Carin Y. Smith; Sarah M. Jenkins; Robert L. Foote; Jan L. Kasperbauer; John C. Morris; Mabel Ryder; Samer Alsidawi; Crystal Hilger; Keith C. Bible

首页> 外文期刊>The journal of clinical endocrinology and metabolism >Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study

【24h】

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study

机译：PD-1和PD-L1在多模式疗法治疗的间变性甲状腺癌患者中的表达：一项回顾性研究的结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

AbstractContext:Anaplastic thyroid cancer (ATC) is rare and a highly fatal malignancy. The role of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) as prognostic and/or predictive markers in ATC is unknown.

机译：摘要背景：变性甲状腺癌（ATC）罕见，是高度致命的恶性肿瘤。程序性死亡1（PD-1）和程序性死亡配体-1（PD-L1）作为ATC预后和/或预测标志物的作用尚不清楚。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2017年第6期|共8页
作者
Ashish V. Chintakuntlawar; Kandelaria M. Rumilla; Carin Y. Smith; Sarah M. Jenkins; Robert L. Foote; Jan L. Kasperbauer; John C. Morris; Mabel Ryder; Samer Alsidawi; Crystal Hilger; Keith C. Bible;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. A Pilot Study of Stereotactic Body Radiotherapy (SBRT) Combined with a PD-L1 Antibody Durvalumab (D) and a CTLA-4 antibody Tremelimumab (T) To Treat Metastatic Anaplastic Thyroid Cancer (ATC) [J] . Lee N., Tsai C. J., Riaz N., International Journal of Radiation Oncology, Biology, Physics . 2019,第1Suppla期

机译：立体定向体放射治疗（SBRT）的试验研究与PD-L1抗体Durvalumab（D）和CTLA-4抗体Tremelimumab（T）进行治疗转移性包塑型甲状腺癌（ATC）
2. Prognostic Factors for Survival in Patients Treated with Multimodal Therapy for Anaplastic Thyroid Cancer [J] . Kaesmann Lukas, Bolm Louisa, Janssen Stefan, Anticancer Research: International Journal of Cancer Research and Treatment . 2016,第9期

机译：变性甲状腺癌多模式疗法治疗患者生存的预后因素
3. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? [J] . Chae Young Kwang, Pan Alan, Davis Andrew A., Clinical lung cancer . 2016,第5期

机译：非小细胞肺癌中PD-1 / PD-L1阻断疗法的生物标志物：PD-L1表达是否是患者选择的良好标志物？
4. The Study on the Relationship between PD-1/PD-L1 mRNA Expression and Progression in HIV/AIDS Patients [C] . Wu Yan-ling, Ding Yan-ping, Cheng Lei, Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：HIV / AIDS患者PD-1 / PD-L1 mRNA表达与疾病进展关系的研究
5. The Role of Online Support for Anaplastic Thyroid Cancer Patients and Survivors [D] . Nixon, Bevin J. 2019

机译：在线支持对共产性甲状腺癌患者和幸存者的作用
6. Human papilloma virus load and PD-1/PD-L1 CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy [O] . Panagiotis Balermpas, Daniel Martin, Ulrike Wieland, 2017

机译：放化疗治疗肛门癌患者的人乳头瘤病毒载量和PD-1 / PD-L1CD8 +和FOXP3：免疫治疗的理由
7. Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy [O] . Konstantinos Rounis, Marcus Skribek, Dimitrios Makrakis, 2021

机译：用PD-1 / Pd-L1抑制剂治疗非小细胞肺癌患者颅内应患者患者颅内癌症的相关性

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study

摘要

著录项

相似文献

相关主题

期刊订阅